{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:05:44Z","timestamp":1761897944191,"version":"build-2065373602"},"reference-count":92,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T00:00:00Z","timestamp":1698537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Splanchnic vein thrombosis (SVT) encompasses thrombosis in the vessels of the splanchnic basin and has a relatively rare occurrence with a reported frequency in the general population of 1\u20132%. An episode of seemingly unprovoked SVT almost always triggers a diagnostic work-up for a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), since atypical site thrombosis is a hallmark of MPN-associated thrombophilia. Primary myelofibrosis (PMF) is a rare MPN with an estimated incidence between 0.1 and 1\/100,000 per year. Although prothrombotic tendency in PMF is not envisioned as a subject of specific therapeutic management, unlike other MPNs, such as polycythemia vera (PV) and essential thrombocythemia (ET), thrombotic risk and SVT prevalence in PMF may be comparably high. Additionally, unlike PV and ET, SVT development in PMF may depend more on procoagulant mechanisms involving endothelium than on blood cell activation. Emerging results from registry data also suggest that PMF patients with SVT may exhibit lower risk and better prognosis, thus highlighting the need for better thrombotic risk stratification and identifying a subset of patients with potential benefit from antithrombotic prophylaxis. This review highlights specific epidemiological, pathogenetic, and clinical features pertinent to SVT in myelofibrosis.<\/jats:p>","DOI":"10.3390\/ijms242115717","type":"journal-article","created":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T05:01:08Z","timestamp":1698555668000},"page":"15717","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Splanchnic Vein Thrombosis in Myelofibrosis\u2014An Underappreciated Hallmark of Disease Phenotype"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2426-6589","authenticated-orcid":false,"given":"Elina A.","family":"Beleva","sequence":"first","affiliation":[{"name":"Clinic of Hematology, Military Medical Academy, 1606 Sofia, Bulgaria"},{"name":"QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of Myelofibrosis, Essential Thrombocythemia, and Polycythemia Vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Barosi, G., Rosti, V., Bonetti, E., Campanelli, R., Carolei, A., Catarsi, P., Isgr\u00f2, A.M., Lupo, L., Massa, M., and Poletto, V. (2012). Evidence That Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035631"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary Myelofibrosis: 2021 Update on Diagnosis, Risk-Stratification and Management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System among Patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Rungjirajittranon, T., Owattanapanich, W., Ungprasert, P., Siritanaratkul, N., and Ruchutrakool, T. (2019). A Systematic Review and Meta-Analysis of the Prevalence of Thrombosis and Bleeding at Diagnosis of Philadelphia-Negative Myeloproliferative Neoplasms. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5387-9"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-020-0289-2","article-title":"Validation of the IPSET Score for Thrombosis in Patients with Prefibrotic Myelofibrosis","volume":"10","author":"Guglielmelli","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1538-7836.2011.04565.x","article-title":"Incidental Diagnosis of a Deep Vein Thrombosis in Consecutive Patients Undergoing a Computed Tomography Scan of the Abdomen: A Retrospective Cohort Study","volume":"10","author":"Ageno","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3748\/wjg.v12.i13.2115","article-title":"Portal Vein Thrombosis: Prevalence, Patient Characteristics and Lifetime Risk: A Population Study Based on 23,796 Consecutive Autopsies","volume":"12","author":"Ogren","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pantic, N., Pantic, I., Jevtic, D., Mogulla, V., Oluic, S., Durdevic, M., Nordin, T., Jecmenica, M., Milovanovic, T., and Gavrancic, T. (2022). Celiac Disease and Thrombotic Events: Systematic Review of Published Cases. Nutrients, 14.","DOI":"10.3390\/nu14102162"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cgh.2009.09.019","article-title":"Survival and Recurrence in Patients With Splanchnic Vein Thromboses","volume":"8","author":"Thatipelli","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood-2014-07-551515","article-title":"How I Treat Splanchnic Vein Thrombosis","volume":"124","author":"Ageno","year":"2014","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/hep.20064","article-title":"Determinants of Survival and the Effect of Portosystemic Shunting in Patients with Budd-Chiari Syndrome","volume":"39","author":"Valla","year":"2004","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/ncpgasthep0143","article-title":"Update on the Classification, Assessment of Prognosis and Therapy of Budd-Chiari Syndrome","volume":"2","author":"Senzolo","year":"2005","journal-title":"Nat. Clin. Pr. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1161\/CIRCULATIONAHA.114.012871","article-title":"Mesenteric Venous Thrombosis","volume":"131","author":"Russell","year":"2015","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jmv.2015.12.001","article-title":"Les thromboses veineuses splanchniques: \u00c9tude monocentrique de 31 cas","volume":"41","author":"Benjilali","year":"2016","journal-title":"J. Mal. Vasc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"522","DOI":"10.5001\/omj.2017.100","article-title":"Portal Vein Thrombosis in Adult Omani Patients: A Retrospective Cohort Study","volume":"32","author":"Pathare","year":"2017","journal-title":"Oman Med. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1365-2036.2010.04454.x","article-title":"The Epidemiology and Clinical Features of Portal Vein Thrombosis: A Multicentre Study","volume":"32","author":"Rajani","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/bjs.6319","article-title":"Epidemiology, Risk and Prognostic Factors in Mesenteric Venous Thrombosis","volume":"95","author":"Acosta","year":"2008","journal-title":"Br. J. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S2352-3026(16)30020-5","article-title":"Clinical History and Antithrombotic Treatment of Incidentally Detected Splanchnic Vein Thrombosis: A Multicentre, International Prospective Registry","volume":"3","author":"Riva","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11899-017-0400-3","article-title":"Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis","volume":"12","author":"Martin","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2016.85","article-title":"High Rate of Recurrent Venous Thromboembolism in Patients with Myeloproliferative Neoplasms and Effect of Prophylaxis with Vitamin K Antagonists","volume":"30","author":"Ruggeri","year":"2016","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative Neoplasms in Budd-Chiari Syndrome and Portal Vein Thrombosis: A Meta-Analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/jgh.14925","article-title":"Prevalence of Prothrombotic Factors in Patients with Budd\u2013Chiari Syndrome or Non-cirrhotic Nonmalignant Portal Vein Thrombosis: A Hospital-based Observational Study","volume":"35","author":"Fan","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2015.3184","article-title":"Long-Term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry","volume":"175","author":"Ageno","year":"2015","journal-title":"JAMA Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1182\/bloodadvances.2020002414","article-title":"Molecular Profiling and Risk Classification of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses","volume":"4","author":"Debureaux","year":"2020","journal-title":"Blood Adv."},{"key":"ref_26","first-page":"2925","article-title":"Splanchnic Vein Thrombosis in Overt Myeloproliferative Neoplasms: The Mayo Clinic Experience with 107 Unselected Consecutive Cases","volume":"130","author":"Lavu","year":"2017","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, Thrombosis, and Anticoagulation in Myeloproliferative Neoplasms (MPN): Analysis from the German SAL-MPN-Registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/ajh.24993","article-title":"Splanchnic Vein Thrombosis in Patients with Myeloproliferative Neoplasms: The Mayo Clinic Experience with 84 Consecutive Cases","volume":"93","author":"Lavu","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","article-title":"Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"26","author":"Vannucchi","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Risk Factors for Recurrences in a Cohort of 181 Patients","volume":"6","author":"Vannucchi","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00277-023-05217-2","article-title":"Pathological and Genomic Features of Myeloproliferative Neoplasms Associated with Splanchnic Vein Thrombosis in a Single-Center Cohort","volume":"102","author":"Cattaneo","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2015.03.009","article-title":"Discrepancies between Bone Marrow Histopathology and Clinical Phenotype in BCR-ABL1-Negative Myeloproliferative Neoplasms Associated with Splanchnic Vein Thrombosis","volume":"39","author":"Gianelli","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ajh.24614","article-title":"Safety and Efficacy of Ruxolitinib in Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms","volume":"92","author":"Pieri","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjh.14958","article-title":"Distinct Clinical, Laboratory and Molecular Features of Myeloproliferative Neoplasm Patients with Splanchnic Vein Thrombosis","volume":"183","author":"How","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.25677","article-title":"Splanchnic Vein Thromboses Associated with Myeloproliferative Neoplasms: An International, Retrospective Study on 518 Cases","volume":"95","author":"Guglielmelli","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ejh.13335","article-title":"Outcomes of Splanchnic Vein Thrombosis in Patients with Myeloproliferative Neoplasms in a Single Center Experience","volume":"104","author":"Tremblay","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e3355","DOI":"10.1097\/MD.0000000000003355","article-title":"\u03b3-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm","volume":"95","author":"Hunka","year":"2016","journal-title":"Medicine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V114.22.309.309","article-title":"High Frequency of Circulating Endothelial Colony Forming Cells (ECFCs) in Myeloproliferative Neoplasms (MPNs) Is Associated with Diagnosis of Prefibrotic Myelofibrosis, History of Splanchnic Vein Thrombosis, and Vascular Splenomegaly","volume":"114","author":"Rosti","year":"2009","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/ijlh.13184","article-title":"JAK2V617F Mutation Prevalence on Chilean Adults Suffering from Primary Mesenteric and Portal Venous Thromboses","volume":"42","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s11239-020-02052-4","article-title":"Portal Vein Thrombosis Patients Harboring JAK2V617F Have Poor Long-Term Outcomes despite Anticoagulation","volume":"50","author":"Naymagon","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2016.12.010","article-title":"CALR Exon 9 Mutations in Idiopathic Splanchnic Vein Thrombosis in an Australian Cohort","volume":"150","author":"Ho","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jhep.2017.04.021","article-title":"Selective Testing for Calreticulin Gene Mutations in Patients with Splanchnic Vein Thrombosis: A Prospective Cohort Study","volume":"67","author":"Poisson","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clml.2014.04.004","article-title":"Clinical Features of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension","volume":"15","author":"Yan","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.thromres.2013.07.014","article-title":"Outcome of Patients with Splanchnic Venous Thrombosis Presenting without Overt MPN: A Role for the JAK2 V617F Mutation Re-Evaluation","volume":"132","author":"Colaizzo","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.leukres.2011.08.008","article-title":"JAK2 46\/1 Haplotype Predisposes to Splanchnic Vein Thrombosis-Associated BCR-ABL Negative Classic Myeloproliferative Neoplasms","volume":"36","author":"Villani","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2010-11-319087","article-title":"The JAK2 46\/1 Haplotype in Budd-Chiari Syndrome and Portal Vein Thrombosis","volume":"117","author":"Smalberg","year":"2011","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/gut.49.5.720","article-title":"Extrahepatic Portal Vein Thrombosis: Aetiology and Determinants of Survival","volume":"49","author":"Janssen","year":"2001","journal-title":"Gut"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.dld.2018.04.004","article-title":"The Epidemiology of Budd-Chiari Syndrome in France","volume":"50","author":"Allaire","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-151-3-200908040-00004","article-title":"Etiology, Management, and Outcome of the Budd-Chiari Syndrome","volume":"151","author":"Plessier","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ibach, M., Eurich, D., Dobrindt, E., Lurje, G., Sch\u00f6ning, W., \u00d6llinger, R., Pratschke, J., and Globke, B. (2021). Orthotopic Liver Transplantation for Budd-Chiari Syndrome: Observations from a 30-Year Liver Transplant Program. Medicina, 57.","DOI":"10.3390\/medicina57080821"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/j.1538-7836.2011.04484.x","article-title":"Long-term Follow-up of Patients with Portal Vein Thrombosis and Myeloproliferative Neoplasms","volume":"9","author":"Hoekstra","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/hep.20591","article-title":"Risk Factors for Thrombophilia in Extrahepatic Portal Vein Obstruction","volume":"41","author":"Primignani","year":"2005","journal-title":"Hepatology"},{"key":"ref_53","first-page":"150","article-title":"The Impact of JAK2V617F Mutation on Philadelphia-Negative Myeloproliferative Neoplasms","volume":"52","author":"Hindilerden","year":"2022","journal-title":"Turk. J. Med. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3389\/fimmu.2019.01373","article-title":"Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms","volume":"10","author":"Heller","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"38738","DOI":"10.1038\/srep38738","article-title":"Neutrophil Extracellular Trap Formation and Circulating Nucleosomes in Patients with Chronic Myeloproliferative Neoplasms","volume":"6","author":"Carestia","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"eaan8292","DOI":"10.1126\/scitranslmed.aan8292","article-title":"Increased Neutrophil Extracellular Trap Formation Promotes Thrombosis in Myeloproliferative Neoplasms","volume":"10","author":"Wolach","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1172\/JCI90312","article-title":"JAK2-V617F Promotes Venous Thrombosis through \u03921\/\u03922 Integrin Activation","volume":"128","author":"Edelmann","year":"2018","journal-title":"J. Clin. Invest."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2017.26","article-title":"JAK2-V617F Activates \u03921-Integrin-Mediated Adhesion of Granulocytes to Vascular Cell Adhesion Molecule 1","volume":"31","author":"Gupta","year":"2017","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1055\/s-0038-1667015","article-title":"Endothelial Cells Harbouring the JAK2V617F Mutation Display Pro-Adherent and Pro-Thrombotic Features","volume":"118","author":"Guadall","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1161\/ATVBAHA.120.314760","article-title":"Platelet Dysfunction and Thrombosis in JAK2V617F-Mutated Primary Myelofibrotic Mice","volume":"40","author":"Matsuura","year":"2020","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F Impairs Hematopoietic Stem Cell Function in a Conditional Knock-in Mouse Model of JAK2 V617F-Positive Essential Thrombocythemia","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"987643","DOI":"10.3389\/fonc.2022.987643","article-title":"Elevated Plasma EDA Fibronectin in Primary Myelofibrosis Is Determined by High Allele Burden of JAK2V617F Mutation and Strongly Predicts Splenomegaly Progression","volume":"12","author":"Malara","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00277-007-0386-3","article-title":"Increased Platelet, Leukocyte, and Coagulation Activation in Primary Myelofibrosis","volume":"87","author":"Reverter","year":"2008","journal-title":"Ann. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3892\/ol.2017.6459","article-title":"Clinical Significance of Circulating Microparticles in Ph\u2212 Myeloproliferative Neoplasms","volume":"14","author":"Zhang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Giordano, G., Napolitano, M., Cellurale, M., Di Carlo, P., Musuraca, G., Micucci, G., and Lucchesi, A. (2022). Circulating Endothelial Cell Levels Correlate with Treatment Outcomes of Splanchnic Vein Thrombosis in Patients with Chronic Myeloproliferative Neoplasms. J. Pers. Med., 12.","DOI":"10.3390\/jpm12030364"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2010-07-297598","article-title":"Endothelial Progenitor Cells Are Clonal and Exhibit the JAK2V617F Mutation in a Subset of Thrombotic Patients with Ph-Negative Myeloproliferative Neoplasms","volume":"117","author":"Teofili","year":"2011","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2040620716680333","article-title":"Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Pathophysiology and Molecular Mechanisms of Disease","volume":"8","author":"How","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and Validation of an International Prognostic Score of Thrombosis in World Health Organization-Essential Thrombocythemia (IPSET-Thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.18440","article-title":"Predictors of Thrombosis and Bleeding in 1613 Myelofibrosis Patients from the Spanish Registry of Myelofibrosis","volume":"199","author":"Raya","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/ejh.13813","article-title":"Survival and Risk of Vascular Complications in Myelofibrosis\u2014A Population-Based Study from the Swedish MPN Group","volume":"109","author":"Lindgren","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41408-022-00743-0","article-title":"Increased Risk of Thrombosis in JAK2 V617F-Positive Patients with Primary Myelofibrosis and Interaction of the Mutation with the IPSS Score","volume":"12","author":"Barbui","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-019-0225-5","article-title":"Addressing and Proposing Solutions for Unmet Clinical Needs in the Management of Myeloproliferative Neoplasm-Associated Thrombosis: A Consensus-Based Position Paper","volume":"9","author":"Barbui","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/ajcp\/aqac173","article-title":"Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early\/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan","volume":"159","author":"Kuo","year":"2023","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jhep.2022.08.023","article-title":"Incidence and Factors Predictive of Recurrent Thrombosis in People with Non-Cirrhotic Portal Vein Thrombosis","volume":"78","author":"Baiges","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s11239-020-02100-z","article-title":"Low Prevalence of JAK2 V617F Mutation in Patients with Thrombosis and Normal Blood Counts: A Retrospective Impact Study","volume":"50","author":"Levraut","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5152\/tjg.2015.5738","article-title":"Diagnostic Value of the JAK2 V617F Mutation for Latent Chronic Myeloproliferative Disorders in Patients with Budd-Chiari Syndrome and\/or Portal Vein Thrombosis","volume":"26","author":"Karakose","year":"2015","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in Primary Myelofibrosis: Incidence and Risk Factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jhep.2020.06.045","article-title":"Next-Generation Sequencing in the Diagnosis of Non-Cirrhotic Splanchnic Vein Thrombosis","volume":"74","author":"Magaz","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2022.08.003","article-title":"Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms","volume":"218","author":"Tremblay","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_80","first-page":"1447","article-title":"Clonal Hematopoiesis by DNMT3A Mutations as a Common Finding in Idiopathic Splanchnic Vein Thrombosis","volume":"108","author":"Giugliano","year":"2023","journal-title":"Haematologica"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41408-018-0100-9","article-title":"Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Algorithm 2018","volume":"8","author":"Finazzi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2014Renewing Consensus in Portal Hypertension","volume":"76","author":"Franchis","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-021-10189-4","article-title":"Budd-Chiari Syndrome: Consensus Guidance of the Asian Pacific Association for the Study of the Liver (APASL)","volume":"15","author":"Shukla","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/apt.15811","article-title":"A Prospective, Multicentre Study in Acute Non-Cirrhotic, Non-Malignant Portal Vein Thrombosis: Comparison of Medical and Interventional Treatment","volume":"52","author":"Bettinger","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1038\/s41375-021-01279-1","article-title":"Direct Oral Anticoagulants for Myeloproliferative Neoplasms: Results from an International Study on 442 Patients","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"key":"ref_86","first-page":"178","article-title":"Prevention and Management of Thrombosis in Myeloproliferative Neoplasms","volume":"15","author":"Sekhar","year":"2017","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ajh.2830460412","article-title":"Outcome of Portal-Systemic Shunt Surgery for Portal Hypertension Associated with Intrahepatic Obstruction in Patients with Agnogenic Myeloid Metaplasia","volume":"46","author":"Tefferi","year":"1994","journal-title":"Am. J. Hematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1111\/liv.12816","article-title":"Long-Term Outcome of Liver Transplant Patients with Budd-Chiari Syndrome Secondary to Myeloproliferative Neoplasms","volume":"35","author":"Potthoff","year":"2015","journal-title":"Liver Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2018.195321","article-title":"Vascular Endothelial Cell Expression of JAK2V617F Is Sufficient to Promote a Pro-Thrombotic State Due to Increased P-Selectin Expression","volume":"104","author":"Guy","year":"2019","journal-title":"Haematologica"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1038\/s41375-022-01673-3","article-title":"Prediction of Thrombosis in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 1258 Patients","volume":"36","author":"Mora","year":"2022","journal-title":"Leukemia"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea Prevents Arterial and Late Venous Thrombotic Recurrences in Patients with Myeloproliferative Neoplasms but Fails in the Splanchnic Venous District. Pooled Analysis of 1500 Cases","volume":"8","author":"Rossi","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/MBC.0000000000000446","article-title":"The Impact of Ruxolitinib on Thrombosis in Patients with Polycythemia Vera and Myelofibrosis: A Meta-Analysis","volume":"27","author":"Samuelson","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/21\/15717\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:13:37Z","timestamp":1760130817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/21\/15717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,29]]},"references-count":92,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["ijms242115717"],"URL":"https:\/\/doi.org\/10.3390\/ijms242115717","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2023,10,29]]}}}